When does the Adbry (tralokinumab) patent expire?
The exact patent expiration date for Adbry depends on which specific patent (or patent family) you mean, because biologics typically have multiple patents covering different aspects such as the molecule, formulation, and method of use. Patent “expiry” can also differ from other dates like regulatory exclusivity.
I don’t have any provided patent or regulatory-exclusivity data for Adbry in the information available here, so I can’t state a reliable expiration date.
Why do Adbry patent dates vary (and what people often mix up)?
Searches for “Adbry patent expire” often mix together several different kinds of timelines:
- Patents covering the drug substance and process (molecule-related)
- Patents covering formulations or delivery
- Method-of-use patents (how it’s prescribed/used)
- Regulatory exclusivity (marketing exclusivity or biologic exclusivity), which can block generic/biosimilar entry even if a particular patent expires
Because these timelines are not the same, “patent expiry” alone may not predict when a biosimilar or competitor can actually launch.
How can you find the specific Adbry patent expiration date?
To get the precise date, you need two details:
1) Jurisdiction (for example, US vs. EU), and
2) The exact patent numbers listed for Adbry in that jurisdiction.
In the US, people commonly use FDA-related listings and Orange Book–style patent registries for that purpose; in Europe, timelines are tracked through national/regional patent authorities and data exclusivity rules.
What happens if a patent expires—can biosimilars launch right away?
Not always. Even if one patent expires, other listed patents can still block approval or launch. Also, regulatory exclusivity periods can continue limiting competition. The answer depends on what remains active at that time.
If you want, I can give the real expiration date
Share either:
- the country/region you care about (US, UK, EU), and
- any patent number(s) you’ve seen for Adbry (or a link),
and I’ll map them to the specific expiration/termination dates and explain what that likely means for biosimilar entry.